Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioAtla, Inc.

0.3438
+0.01966.05%
Post-market: 0.34380.00000.00%18:51 EDT
Volume:488.35K
Turnover:165.98K
Market Cap:19.95M
PE:-0.20
High:0.3499
Open:0.3400
Low:0.3301
Close:0.3242
Loading ...

BioAtla Awards Executive Bonuses and Stock Units

TIPRANKS
·
15 Mar

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

Zacks
·
03 Jan

BioAtla Secures $9.2M for Clinical Program Advancements

TIPRANKS
·
21 Dec 2024

BioAtla Prices Registered Direct Offering of 9.7 Million Shares for Expected Gross Proceeds of $9.2 Million

MT Newswires Live
·
20 Dec 2024

BioAtla Highlights Advancements in CAB Cancer Therapy

TIPRANKS
·
20 Dec 2024

BioAtla to sell 9.68M shares at 95.2c in registered direct offering

TIPRANKS
·
20 Dec 2024

Bioatla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

THOMSON REUTERS
·
20 Dec 2024

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

GlobeNewswire
·
20 Dec 2024

Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

Simply Wall St.
·
18 Dec 2024

BioAtla presents data on mecbotamab vedotin in advanced NSCLC

TIPRANKS
·
16 Dec 2024

Bioatla Presented Data Characterizing Mutated Kras Genotype and Clinical Outcomes in Patients With Advanced Nsclc Treated With Mecbotamab Vedotin (Mec-V), a Cab-Axl-ADC, at the Iaslc 2024 Hot Topic in Basic & Translational Science Meeting

THOMSON REUTERS
·
16 Dec 2024

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

GlobeNewswire
·
16 Dec 2024

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

GlobeNewswire
·
10 Dec 2024

Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades

seekingalpha
·
15 Nov 2024

BioAtla Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

HC Wainwright Downgrades BioAtla to Neutral From Buy

MT Newswires Live
·
13 Nov 2024